Drug Clinical Trials:
News on drug clinical trials, articles on tests or new drugs and medication.
-
Dec 10th, 2008
Positive data from three phase III studies show that Zebinix significantly reduced the frequency of partial seizures and has the potential to significantly improve quality of life and depressive symptoms in patients with partial refractory epilepsy, in combination with other anti-epileptic agents.
-
Dec 9th, 2008
Amgen Inc. released updated results from the ongoing, open-label extension study of the long-term safety and efficacy of Nplate (romiplostim) in adult patients with chronic immune thrombocytopenic purpura (ITP).
-
Dec 9th, 2008
New data from the largest prospective trial in iron chelation demonstrate the efficacy and safety of Exjade (deferasirox) in treating chronic transfusional iron overload.
-
Dec 8th, 2008
More than half (53.6%) of those moderate to severe Crohn's disease patients who had open fistulas at baseline had closure of fistulas by Week 26 following short-term induction therapy with CIMZIA (certolizumab pegol).
-
Dec 5th, 2008
OncoGenex Pharmaceuticals provided positive survival results from a randomized Phase 2 clinical trial of OGX-011 in combination with docetaxel and prednisone compared to docetaxel and prednisone alone for first-line treatment of metastatic castrate resistant prostate cancer.
-
Dec 3rd, 2008
Vanda Pharmaceuticals publishes results of clinical trials of its novel circadian regulator, experimental compound tasimelteon (VEC-162).
-
Nov 26th, 2008
Pharmacyclics has completed a Phase 1 clinical trial with PCI-27483, the company's novel, first-in-class small-molecule Factor VIIa inhibitor.
-
Nov 25th, 2008
The New York Times series examine the growing movement among researchers to conduct pragmatic, or real world, clinical trials to gather evidence that will fill some of the biggest gaps in medical science: What treatment is best for typical patients with complex symptoms?
-
Nov 20th, 2008
The study looks at physicians' attitudes and beliefs about recruiting patients to clinical trials, particularly minorities.
-
Nov 19th, 2008
The hiring of 12 new reviewers for the FDA’s Division of Drug Marketing, Advertising and Communications (DDMAC) is allowing the agency to beef up its scrutiny of Pharma promotional materials.
